In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...

The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer. A phase 3 ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable ...

Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...

KEYNOTE-C93 demonstrated BICR-assessed PFS superiority for pembrolizumab monotherapy over platinum doublet chemotherapy in frontline dMMR advanced/recurrent endometrial cancer. Overall survival ...

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses ...

OptiTROP-Lung06 demonstrated statistically significant, clinically meaningful PFS improvement for sac-TMT plus pembrolizumab versus pembrolizumab plus pemetrexed/platinum in first-line driver-negative ...

Tucidinostat plus nivolumab achieved statistically significant PFS benefit over nivolumab plus placebo in treatment-naive advanced melanoma, with median PFS 11.7 vs 7.4 months. HBI-8000-303 randomized ...